E-Chiang Lee
Executive VP of Research
E-Chiang is the Executive Vice President of Research at T-Therapeutics, responsible for establishing the Research strategy, directing drug discovery and translational efforts to bring molecules to the developmental candidate stage, and continuously evolving the technology.
Previously, E-Chiang was Head of Research UK at Sanofi after Kymab’s acquisition, overseeing integration and re-building of bispecific pipeline focusing on immune-oncology and autoimmune diseases.
Prior to this role, he was the VP Technology at Kymab, leading multidisciplinary teams to build all corner stone technologies from Kymouse, single-cell technology to bi-specific platform, which drove three molecules into the clinical programs including amlitelimab.
E-Chiang was a founding scientist at Kymab. He was an inventor of more than 100 granted patents across recombineering, transgenic platforms, single-cell application, and therapeutic antibodies. He completed his PhD in Albert Einstein College of Medicine and post-doctoral training at NCI.
